University Hospital Coventry and Warwickshire NHS Trust, Clifford Bridge Road, Coventry, CV2 2DX, UK.
Knee Surg Sports Traumatol Arthrosc. 2019 Jun;27(6):1908-1913. doi: 10.1007/s00167-019-05437-y. Epub 2019 Feb 28.
The need for meniscal allograft transplantation (MAT) in children is rare, and as a result, there is a paucity of evidence detailing survivorship and clinical outcome. MAT has been shown to significantly reduce pain and improve function in the adult population. The aim of this study was to document the outcomes of a single surgeon case series of MAT in the paediatric population.
Analysis of a prospective meniscal allograft transplantation (MAT) group database of 280 patients was performed. Twenty-three patients met the inclusion criteria-undergoing MAT aged 18 years or younger.
Fourteen were female and nine were male with median age of 17 (range 8-18). Thirteen (57%) were right knee and nineteen (83%) were lateral. Additional procedures included high tibial osteotomy, anterior cruciate ligament reconstruction, and microfracture procedures. The median follow-up was 3.8 years (range of 0.2 to 7.8 years). There have been no cases of graft failure. All patients demonstrated improvement in all the modalities of the KOOS outcome scores. At 5 years, the Lysholm score had improved from 57.9 to 87.6 (SD 12.1), Tegner activity score had improved from 2 to 5 (range 4-7) and IKDC score had improved from 40.6 to 78.6 (SD 15.8). Four patients required secondary surgical intervention. No patients developed a superficial or deep infection.
Meniscal allograft transplantation in children is founded on the successful results of MAT in the adult population. We have demonstrated in this series that MAT can improve function and reduce pain in the paediatric population, and is, therefore, a viable treatment option for the management of the symptomatic paediatric meniscal-deficient knee. Early referral should be considered in the patients with post-meniscectomy syndrome, pain on weight bearing with a history of previous menisectomy.
IV.
儿童半月板同种异体移植(MAT)的需求很少,因此,详细描述生存率和临床结果的证据也很少。MAT 已被证明可显著减轻成年人的疼痛并改善功能。本研究的目的是记录一位外科医生对儿童半月板同种异体移植(MAT)病例系列的结果。
对 280 例患者的前瞻性半月板同种异体移植(MAT)组数据库进行分析。23 例符合纳入标准,即年龄在 18 岁或以下接受 MAT。
14 例为女性,9 例为男性,平均年龄为 17 岁(范围为 8-18 岁)。13 例(57%)为右膝,19 例(83%)为外侧。其他手术包括胫骨高位截骨术、前交叉韧带重建术和微骨折术。中位随访时间为 3.8 年(范围为 0.2 至 7.8 年)。无移植物失败病例。所有患者的 KOOS 结果评分的所有模式均显示改善。在 5 年时,Lysholm 评分从 57.9 提高到 87.6(标准差 12.1),Tegner 活动评分从 2 提高到 5(范围 4-7),IKDC 评分从 40.6 提高到 78.6(标准差 15.8)。有 4 例患者需要进行二次手术干预。无患者发生浅表或深部感染。
儿童半月板同种异体移植是基于成人 MAT 的成功结果。我们在本系列中证明,MAT 可以改善儿童人群的功能并减轻疼痛,因此,是治疗有症状的儿童半月板缺失膝关节的可行治疗选择。对于有半月板切除术后综合征、负重疼痛且有半月板切除术病史的患者,应早期转诊。
IV。